New autoimmune drug JANX011 enters first human safety trial

NCT ID NCT07291323

Recruiting now Knowledge-focused Sponsor: Janux Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests the safety of a new drug called JANX011 in 60 healthy adults. Researchers will give a single dose and monitor for side effects. The goal is to gather initial safety data before testing in people with autoimmune diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JANX011
What this could lead to: If safe, this could lead to a new treatment option for autoimmune diseases.
What could go wrong: This is an early Phase 1 study in healthy volunteers, not patients. It only tests safety and dosing, not effectiveness. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE

Contacts and locations

Locations

CMAX
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.